恒瑞医药： 1 类创新药 SHR-1918 注射液上市许可申请获受理被纳入优先审评程序

Core Viewpoint - Heng Rui Medicine announced that its innovative drug, SHR-1918 injection, a fully human monoclonal antibody targeting ANGPTL3, has received acceptance for its drug listing application and has been included in the priority review process for treating adult and adolescent patients aged 12 and above with homozygous familial hypercholesterolemia (HoFH) [1] Group 1 - SHR-1918 injection is independently developed by Heng Rui Medicine as a fully human anti-ANGPTL3 monoclonal antibody [1] - The mechanism of SHR-1918 involves inhibiting the activity of ANGPTL3, leading to a reduction in serum triglycerides (TG) and LDL-C levels [1]